Skip to content

Pacira BioSciences

US · PCRX #3244 by market cap
36.48 0.00 0.00%
Periodic snapshot; not a real-time feed. · 2026-11-19 19:54

Price chart

36.4922.2536.482026-05-212026-11-18
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PCRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +50.8% on average (3-month/1-year).
  • Short interest has fallen to 8.4% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall C-
ValuationGrowthProfitMomentumHealthAnalyst
Valuation C

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 39.2x Better than 14%
Forward P/E 33.8x Better than 14%
Price / Sales 2.0x Better than 58%
P/E vs own 5-yr range 44th pctl Better than 65%
Growth C-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 2.9% Better than 38%
Net income CAGR (3Y) -23.8% Better than 15%
Free cash flow CAGR (3Y) 5.9% Better than 47%
Profitability C+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 79.4% Better than 90%
Operating margin 2.6% Better than 28%
Net margin 1.0% Better than 29%
Return on equity 1.0% Better than 29%
Return on invested capital 0.1% Better than 28%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 47.9% Better than 100%
6-month return 56.2% Better than 96%
12-month return (ex latest month) 57.7% Better than 87%
Distance below 52-week high 0.5% Better than 99%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.5x Better than 84%
Debt to assets 33.1% Better than 36%
Interest coverage 2.2x Better than 38%
Free cash flow / net income 1,942.9% Better than 98%
Analyst View F

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 0.0% Better than 0%
Upside to average target -4.6% Better than 2%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +0.05%
1M +0.39%
3M +52.00%
6M +62.57%
YTD +40.96%
1Y +49.57%
3Y +30.80%
5Y -35.16%

Key statistics

Price & volume

Prev close
36.48
Open
0.00
Day range
0.00 - 0.00
Avg price
0.00
Volume
0
Turnover
0
Amplitude
0.00%
52-week range
18.80 - 36.67

Valuation

P/E
228.00
P/E (TTM)
39.23
P/B
2.05
EPS
0.16
Net profit
6.42M
Net assets
712.32M

Share structure

Market cap
1.46B
Float cap
1.44B
Shares out
40.09M
Float shares
39.53M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 99% of range
18.80 36.67

0.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-23.08M net over the window

Short interest

Shares short
3.35M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Pacira BioSciences (PCRX)?

Pacira BioSciences last traded at 36.48. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Pacira BioSciences's market cap?

About 1.46B.

What is the P/E ratio of Pacira BioSciences?

The trailing twelve-month P/E is 39.23, above its own 5-year average of 29.09 — in the middle of its historical range (44.45% percentile). See the Valuation tab for the full history.

Does Pacira BioSciences pay a dividend?

Pacira BioSciences does not currently pay a regular dividend.

Is Pacira BioSciences a buy according to analysts?

The consensus of 9 analysts is a Hold rating, with an average 12-month price target of 34.79, which implies 4.6% downside from the current price. This is not investment advice.

What is Pacira BioSciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Pacira BioSciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-19 19:54:59 · For reference only, not investment advice and not tailored to your situation.

Pacira BioSciences discussion 0 comments

Add a comment